Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: W.B. Saunders for the American Gastroenterological Association Country of Publication: United States NLM ID: 101160775 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1542-7714 (Electronic) Linking ISSN: 15423565 NLM ISO Abbreviation: Clin Gastroenterol Hepatol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Philadelphia, PA : W.B. Saunders for the American Gastroenterological Association, 2003-
    • Subject Terms:
      Drug Resistance, Viral* ; Mutation, Missense*; DNA-Directed DNA Polymerase/*genetics ; Hepatitis B virus/*enzymology ; Hepatitis B virus/*genetics ; Hepatitis B, Chronic/*virology; Adolescent ; Adult ; Aged ; California/epidemiology ; Cross-Sectional Studies ; DNA, Viral/genetics ; Female ; Genotyping Techniques ; Hepatitis B virus/isolation & purification ; Hepatitis B, Chronic/drug therapy ; Hepatitis B, Chronic/epidemiology ; Humans ; Male ; Middle Aged ; Prevalence ; Prospective Studies ; Surveys and Questionnaires ; Young Adult
    • Abstract:
      Background & Aims: Prior studies have detected hepatitis B virus (HBV) DNA polymerase mutations in treatment-naive patients. However, most of these studies used either direct polymerase chain reaction sequencing, which detects these mutations with low levels of sensitivity, or patient cohorts that were not well-characterized. We investigated the prevalence of HBV mutations in DNA polymerase by using a line probe assay.
      Methods: In a prospective, cross-sectional study, we enrolled 198 treatment-naive patients with chronic hepatitis B (52.5% male; mean age, 41 years) from February 2009 to May 2011 from 3 gastroenterology and liver clinics in Northern California. Exclusion criteria included infection with hepatitis C or D viruses or human immunodeficiency virus. All patients completed a questionnaire (to determine demographics, history of liver disease, prior treatments, family medical history, drug and alcohol use, and environmental risk factors for hepatitis) that was administered by a research coordinator; mutations in HBV DNA polymerase were detected by using the INNO-LiPA HBV DR v.3 assay.
      Results: Most patients were Vietnamese (48.5%) or Chinese (36.4%) and were infected with HBV genotypes B (67.5%) or C (24.2%). Mutations in HBV DNA polymerase were found in 2 patients (1%), rtI233V (n = 1) and rtM250M/L (n = 1).
      Conclusions: In a multicenter prospective study of treatment-naive patients with chronic hepatitis B, we detected mutations in HBV DNA polymerase in only 1%. Because of the low prevalence of these mutations and the uncertain clinical significance of such quasispecies, routine HBV DNA polymerase mutation analysis cannot be recommended before initiation of antiviral therapy for treatment-naive patients with chronic hepatitis B. The analysis requires further molecular and clinical studies.
      (Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.)
    • Contributed Indexing:
      Keywords: Baseline; CHB; Reverse; Transcriptase
    • Accession Number:
      0 (DNA, Viral)
      EC 2.7.7.7 (DNA-Directed DNA Polymerase)
    • Publication Date:
      Date Created: 20131218 Date Completed: 20150312 Latest Revision: 20151119
    • Publication Date:
      20240829
    • Accession Number:
      10.1016/j.cgh.2013.11.036
    • Accession Number:
      24342744